Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2006-2014

  Adkins, D ^a   Brown, R ^b   Trinkaus, K ^b   Maziarz, R ^b   Luedke, S ^b   Freytes, C ^b   Needles, B ^b   Wienski, D ^b   Fracasso, P ^b   Pluard, T ^b   Moriconi, W ^b   Ryan, T ^b   Hoelzer, K ^b   Safdar, S ^b   Rearden, T ^b   Rodriguez, G ^b   Khoury, H ^b   Vij, R ^b   DiPersio, J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; MELPHALAN; PACLITAXEL; TAMOXIFEN; THIOTEPA;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MASTECTOMY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032983493     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2006     Document Type: Article

References (44)

1. Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: A review. J Clin Oncol 10:1014-1024, 1992
2. Perez CA, Fields JN, Fracasso PM, et al: Management of locally advanced carcinoma of the breast: II. Inflammatory carcinoma. Cancer 74:466-476, 1994 (suppl 1)
3. Zucali R, Uslenghi C, Kenda R, et al: Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer 37:1422-1431, 1976
4. Barker JL, Montague ED, Peters LJ: Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer 45:625-629, 1980
5. Bozzetti F, Saccozzi R, De Lena M, et al: Inflammatory cancer of the breast: Analysis of 114 cases. J Surg Oncol 18:355-361, 1981
6. Rao V, Bedwinek J, Perez C, et al: Prognostic indicators in stage III and localized stage IV breast cancer. Cancer 50:2037-2043, 1982
7. Rouëssé J, Friedman S, Sarrazin D, et al: Primary chemotherapy in the treatment of inflammatory breast carcinoma: A study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 4:1765-1771, 1986
8. Swain SM, Sorace RA, Bagley CS, et al: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889-3894, 1987
9. Thoms WM, McNeese MD, Fletcher GH, et al: Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 17:739-745, 1989
10. Fields JN, Perez CA, Kuske RR, et al: Inflammatory carcinoma of the breast: Treatment results on 107 patients. Int J Radiat Oncol Biol Phys 17:249-255, 1989
11. Koh EH, Buzdar AU, Ames FC, et al: Inflammatory carcinoma of the breast: Results of a combined-modality approach - M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 27:94-100, 1990
12. Maloisel F, Dufour P, Bergerat JP, et al: Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 65:851-855, 1990
13. Chevallier B, Bastit P, Graic Y, et al: The Centre H. Becquerel studies in inflammatory non metastatic breast cancer: Combined modality approach in 178 patients. Br J Cancer 67:594-601, 1993
14. Attia-Sobol J, Ferriére JP, Curé H, et al: Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: Univariate and multivariate analysis. Eur J Cancer 29A:1081-1088, 1993
15. Palangie T, Mosseri V, Mihura J, et al: Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 30A:921-927, 1994
16. Thomas F, Arriagada R, Speilmann M, et al: Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer 76:2286-2290, 1995
17. Buzdar A, Hortobagyi G, Wasaff B, et al: Combined modality approach (CMA) for inflammatory carcinoma of breast (IBC): 20 year (YRS) experience of M.D. Anderson Cancer Center. Proc Am Soc Clin Oncol 14:92a, 1995 (abstr 67)
18. Morvan F, Espie M, Mignot L, et al: 15 years follow up for T4d (inflammatory) breast cancer patients. Proc Am Soc Clin Oncol 14:141a, 1995 (abstr 265)
19. Antman K, Gale RP: Advanced breast cancer: High-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 108:570-574, 1988
20. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376, 1988
21. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
22. Peters WP, Berry D, Vredenburgh JJ, et al: Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes (Duke/CALGB 8782). Proc Am Soc Clin Oncol 14:317a, 1995 (abstr 933)
23. Spitzer G, Adkins DR, Spencer V, et al: Randomized study of growth factors post-peripheral blood stem cell transplant: Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 12:661-670, 1994
24. Kouides PA, Abboud CN, Frediani KE, et al: The infusion of mobilized peripheral blood stem cells (PBSCs) alone after myeloablative therapy can accelerate hematopoietic recovery as rapidly as mobilized PBSCs with autologous bone marrow (ABM). Blood 82: 289a, 1993 (suppl 1; abstr)
25. Kennedy MJ, Beveridge RA, Rowley SD, et al: High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920-926, 1991
26. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992
27. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
28. Bensinger WI, Schiffman KS, Holmberg L, et al: High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant 19:1183-1189, 1997
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Ayash LJ, Elias A, Ibrahim J, et al: High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 16:1000-1007, 1998
31. Buzdar AU, Singletary SE, Booser DJ, et al: Combined modality treatment of stage III and inflammatory breast cancer. Surg Oncol Clin North Am 4:715-734, 1995
32. Antman KH, Rowlings PA, Vaughan P, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870-1879, 1997
33. Cagnoni PJ, Nieto Y, Shpall EJ, et al: High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 16:1661-1668, 1998
34. Somlo G, Doroshaw JH, Forman SJ, et al: High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: Prognostic indicators of progression-free and overall survival. J Clin Oncol 15:2882-2893, 1997
35. García-Carbonero R, Hidalgo M, Paz-Ares L, et al: Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer. J Clin Oncol 15:3178-3184, 1997
36. Crump M, Goss PE, Prince M, et al: Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 14:66-69, 1996
37. Nieto Y, Cagnoni PJ, Jones RB: Standard versus high-dose therapy in 10+ breast cancer. J Clin Oncol 16:810, 1998 (letter)
38. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences, and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
39. Palangié, Bourgeois H, Texier V, et al: High pathological response rate in inflammatory breast cancer (IBC) with multiple cycle high dose chemotherapy and peripheral blood progenitor cells (PBPC) support. Proc Am Soc Clin Oncol 15:337a, 1996 (abstr 974)
40. Fisher ER, Redmond C, Fisher B: Pathologic findings from the National Surgical Adjuvant Breast Project: VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer 51: 181-191, 1983
41. Fisher B, Fisher ER, Redmond C: Ten year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4:929-941, 1986
42. Zambetti M, Bonadonna G, Valagussa P, et al: Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. Monogr Natl Cancer Inst 11:77-83, 1992
43. O'Reilly SM, Camplejohn RS, Millis RR, et al: Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 26:1035-1038, 1990
44. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994